Compare ADUS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | MNKD |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2009 | 2004 |
| Metric | ADUS | MNKD |
|---|---|---|
| Price | $99.48 | $2.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $136.40 | $8.64 |
| AVG Volume (30 Days) | 198.1K | ★ 6.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 5.22 | 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $9.17 | $33.40 |
| Revenue Next Year | $4.64 | $16.48 |
| P/E Ratio | ★ $19.16 | $126.00 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $89.75 | $2.48 |
| 52 Week High | $124.44 | $6.51 |
| Indicator | ADUS | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 21.39 |
| Support Level | N/A | $2.52 |
| Resistance Level | $118.50 | $6.18 |
| Average True Range (ATR) | 2.83 | 0.14 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 18.34 | 19.83 |
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.